Background: Serum HBV DNA level is crucial in the management of chronic hepatitis B (CHB); however, the assay is expensive and cannot be used widely. Therefore, we explored the possibility of hepatitis B surface antigen (HBsAg) quantification as a surrogate marker for HBV DNA level in CHB patients. Methods: A total of 289 CHB patients were enrolled, 251 were evaluated at baseline and 75 of them were also evaluated during anti-HBV treatment. Another 38 ontreatment patients were used for validation. Serum HBsAg titre was quantified by an immunoassay and HBV DNA level by a PCR-based method. Baseline and on-treatment data were analysed. Results: In parallel to log 10 HBV DNA, the log 10 HBsAg was high in both immune tolerance and immune clearance phases, and significantly decreased in the inactive carrier state and was again increased in the reactivation phase of the CHB infection. There was a positive correlation between log 10 HBsAg and log 10 HBV DNA, which was greater in patients with chronic hepatitis, hepatitis B e antigen-positivity, greater alanine aminotransferase or HBsAg levels at baseline and during pegylated interferon treatment. Log 10 HBsAg could predict log 10 HBV DNA independently. An HBsAg titre of >900 IU/ml at baseline or >1,500 IU/ml within the first year of treatment could predict an HBV DNA level of >20,000 IU/ml, especially in subgroups of chronic hepatitis with alanine aminotransferase levels >40 IU/l. The dynamics of HBsAg might also predict serial HBV DNA changes. In the validation group, 64% of patients with on-treatment HBV DNA levels >20,000 IU/ml could be correctly predicted. Conclusions: Serum HBsAg concentration might serve as a surrogate marker of HBV DNA level in CHB patients.
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More than 350 million people have chronic HBV infection worldwide, which causes chronic hepatitis (CH), liver cirrhosis (LC) and hepatocellular carcinoma (HCC) and thus poses a great threat to public health [1] . Several serological and molecular markers have been introduced for the diagnosis of chronic hepatitis B (CHB). Recently, periodic monitoring of serum HBV DNA levels has become valuable in the management of chronic HBV infection. It allows the assessment of liver disease severity, the differentiation of other aetiologies of hepatitis, the prediction of risks of longterm outcomes, allows decisions to be made regarding receiving antiviral therapy, allows the monitoring of treatment responses and the detection of the emergence of drug-resistant mutants [2] . However, HBV DNA quantification is still expensive and, more importantly, it is not easily accessible or affordable in developing countries where HBV infection is extensive.
Compared with molecular assays, HBV serological assays are relatively inexpensive and have been widely used [2, 3] . Among these serological markers, hepatitis B surface antigen (HBsAg) is the hallmark of active HBV 1, 2, 6 , Pei-Jer Chen 1, 2, 6 , Ming-Yang Lai 1, 2, 6 , Ding-Shinn Chen 1, 2, 6 , Jia-Horng Kao 1, 2, 6 Introduction infection and 1 ng of HBsAg corresponds to approximately 5×10 7 HBV particles [4] . It is, thus, theoretically possible to use HBsAg quantification as a surrogate marker of serum HBV DNA levels and earlier studies using semiquantitative methods also indicated the feasibility of such an approach [5, 6] .
With recent advances in HBsAg quantitative technology, a good correlation has been found between HBsAg titre and HBV DNA level in treatment-naive CHB patients [7] [8] [9] and those with pegylated interferon (PEG-IFN) or lamivudine (3TC) treatment [10] . By contrast, several recent reports indicated a lack of correlation between HBsAg and HBV DNA levels in HBsAg-positive blood donors [11] , organ transplant recipients [12] and patients during anti-HBV therapy [13] . These discrepant results could be accounted for by heterogeneous patient populations with limited case numbers and non-standardized HBsAg or HBV DNA quantitative assays; therefore, the correlation between HBsAg titre and HBV DNA level is still undecided and deserves further investigation.
In this study, the primary aim was to revisit the correlation between quantitative HBsAg titre and HBV DNA level in CHB patients before treatment, and the secondary aim was to elucidate the role of quantitative HBsAg titre in monitoring CHB patients receiving anti-HBV treatments.
Methods

Patients
From March 2002 to April 2008, we randomly enrolled 295 CHB patients who were HBsAg-positive for >6 months and who were regularly followed at the gastroenterology clinics of the National Taiwan University Hospital (Taipei, Taiwan). We excluded patients with heavy alcohol use (alcohol >20 g/day), malignancies other than HCC and other causes of liver diseases.
In total, 289 eligible patients were included in our study. Among them, 219 treatment-naive patients and 32 off-treatment patients (non-responders, with a treatment-free interval >1 year) were designated the 'baseline group' (n=251); 75 patients from the baseline group who later received anti-HBV therapy were designated the 'treatment group'. Regarding antiviral agents, 3TC was given to 27, adefovir dipivoxil (ADV) to 15, entecavir (ETV) to 24 and PEG-IFN to 9 patients. Another 38 on-treatment patients (3TC in 23, ADV in 10, ETV in 3 and PEG-IFN in 2) without baseline HBsAg titre or HBV DNA level were designated as the 'validation group'. Their serum samples at baseline and during treatment were retrieved from our serum bank (stored at -20°C in refrigerators) for further analysis. This study was performed in accordance with the principles of the Declaration of Helsinki and was approved by the Institutional Review Board of the National Taiwan University Hospital. Written informed consent was obtained from each participant.
Quantification of hepatitis B surface antigen
Serum HBsAg titre was quantified by a commercial chemiluminescent microparticle immunoassay (ARCHI-TECT ® ; Abbott Laboratories, Abbott Park, IL, USA) with a diagnostic range of 0.05-250 IU/ml [7] . Serial 1:500 dilutions were performed, in case the HBsAg levels were >250 IU/ml, according to the manufacturer's instructions.
Quantification and genotyping of HBV DNA
Serum HBV DNA was extracted from 200 ml serum using a QIAmp DNA Blood Mini Kit (QIAGEN Inc., Valencia, CA, USA) and quantified by a real-time PCR amplification assay using a LightCycler (Roche Diagnostics, Basel, Switzerland) with a detection sensitivity of 20 IU/ml, along with the HBV genotyping by the melting curve analysis [14] . If serum HBV DNA level was undetectable, the low detection limit of the assay (20 IU/ml) was assigned.
Statistical analyses
Descriptive values were expressed as mean ± standard deviation and percentage accordingly. The one-way ANOVA or Student's t-test was used for data comparison between continuous variables and the c 2 test for categorical data. Pearson's correlations were used to evaluate the associations between log 10 HBsAg and log 10 HBV DNA. Univariate and multivariate regression analyses were used to identify the significant predictors for HBV DNA level. Because HBV DNA levels of 2,000 and 20,000 IU/ml were important clinical indicators during management [15] , the receiver operating characteristic (ROC) curve analysis was used to determine the best cutoff level of HBsAg titre for prediction. The P-values were two-tailed and those where P<0.05 were considered as statistically significant. The statistical analyses were performed using Stata software version 8.2 (StataCorp., College Station, TX, USA).
Results
Patient characteristics
There were 196 men and 93 women included with a mean age of 47 years (range 19-85). Overall, 38% of participants had normal (≤40 IU/l) alanine aminotransferase (ALT) levels, 25% had HBV DNA levels <2,000 IU/ml and 3% of participants had HBV DNA levels <20 IU/ ml. All patients were infected with HBV genotypes B and C. The demographic data of the baseline and treatment groups are listed in Tables 1 and 2 , respectively. In the baseline group, the average log 10 HBsAg was 3.02 IU/ ml and decreased consistently with advancing age. The average log 10 HBV DNA was 4.96 IU/ml. Patients in the baseline group were stratified by their natural course of infection into 'immune tolerance', 'immune clearance', 'inactive carrier state' and 'reactivation' phases. Both log 10 HBsAg and log 10 HBV DNA levels decreased significantly (P<0.001) in the inactive carrier state and increased again in the reactivation phase. In addition, the mean ±sd log 10 HBsAg was significantly higher in hepatitis B e antigen (HBeAg)-positive patients than in HBeAg-negative patients (3.78 ±1.01 versus 2.65 ±1.00 IU/ml; P<0.001), but was comparable in terms of gender and genotypes.
In the treatment group, the mean number of ontreatment days was 311 (median 255), which was significantly longer in the 3TC group, but comparable in the ADV, ETV and PEG-IFN groups. The on-treatment log 10 HBsAg level of the PEG-IFN group and the log 10 HBV DNA level of the ETV group became significantly lower compared with other regimens. A significant ontreatment log 10 HBsAg reduction was only found in the 3TC (P=0.016) and PEG-IFN (P=0.028) groups, whereas the on-treatment log 10 HBV DNA was reduced substantially in all regimens (all P<0.001).
Correlation analyses
The Pearson's correlation was moderate between log 10 HBsAg and log 10 HBV DNA in the baseline and treatment groups (0.57 versus 0.53; both P<0.001), respectively ( Figure 1 ). In order to find the most appropriate candidates for quantitative HBsAg titres in clinical use, we stratified the patients by age (≤50 and >50 years), gender, genotype (B and C), liver disease status (CH, LC and HCC by abdominal ultrasonography and clinical information), HBeAg status, ALT level (≤40 versus >40 versus >400 IU/l) and HBsAg titre (≤250 versus >250 versus >2,500 IU/ml) for comparisons. The correlation was comparable (between 0.52 and 0.63) in different age, gender and HBV genotype subgroups, but was higher in the subgroup of CH and HBeAg-positive patients in both the baseline and treatment groups. Patients with higher serum ALT levels (>40 IU/l) or HBsAg titre (>250 IU/ml) had a greater correlation coefficient with a dose-response trend, especially in those with baseline HBsAg levels >2,500 IU/ml (correlation 0.69; P<0.001). Among the four phases of chronic HBV infection, the correlation was higher in the immune tolerance, immune clearance and reactivation phases 
Univariate and multivariate regression analyses
In the baseline group, the univariate linear regression analysis showed significant correlations between age, HBeAg-positivity, ALT levels and log 10 HBsAg versus log 10 HBV DNA (all P<0.001). After adjustment for age, gender, HBV genotype, liver disease status, HBeAgpositivity and ALT levels, the multivariate analysis showed a significant linear regression between HBeAgpositivity, ALT levels and log 10 HBsAg versus log 10 HBV DNA (all P<0.001; Additional file 1). The log 10 HBsAg remained an independent predictor of log 10 HBV DNA during treatment (P<0.001).
Receiver operating characteristic curve analyses
In the baseline group, we found that an HBsAg titre of >400 IU/ml had a sensitivity of 80% and a specificity of 55% to predict serum HBV DNA levels of >2,000 IU/ ml. We also found that an HBsAg titre of >900 IU/ml had a sensitivity of 78% and a specificity of 58% to predict serum HBV DNA levels of >20,000 IU/ml (Table 3) . According to the results from the correlation analysis, we included patients of CH, HBeAg-positivity, ALT levels >40 IU/l or ALT levels >400 IU/l for subgroup analysis and a greater predictability with increasing area under the curve (AUC) was found with an average sensitivity and positive predictive value (PPV) of 80% and specificity of approximately 60%. An AUC of 0.93 was found in the subgroup of ALT levels >400 IU/l with both sensitivity and specificity >90%; however, a high sensitivity (87%) but low specificity (18%) was observed in the subgroup of HBeAg-positive patients, possibly because the majority of participants (71/82) had HBV DNA levels >20,000 IU/ml.
In the treatment group (Table 4) , HBsAg titre also demonstrated a good power to predict serum HBV DNA levels. The sensitivity and specificity, by using an HBsAg titre of >1,500 IU/ml to predict serum HBV DNA levels of >20,000 IU/ml, were 78% and 67%, respectively, with a negative predictive value (NPV) of 90%. A greater predictability was also found during subgroup analysis, with an average of 85% sensitivity, 70% specificity and 90% NPV. In both the baseline and treatment groups, patients of CH and ALT levels >40 IU/l were better candidates to use such prediction. The serial HBsAg dynamics also had a good prediction of corresponding HBV DNA level change. For example, by comparing the baseline and first on-treatment measurement, we found that this on-treatment HBsAg decrease had a PPV of 95% to predict HBV DNA reduction (sensitivity 78% and specificity 63%). In 13 patients with a second on-treatment measurement of HBsAg and HBV DNA, the subsequent HBsAg increase to predict an HBV DNA increase had a PPV of 70% and an NPV of 100%. An additional 24 patients with offtreatment HBsAg titres who showed an HBsAg increase had a PPV of 77% to predict HBV DNA increase, suggesting a possible virological relapse (sensitivity 71% and specificity 70%).
Validation analyses
The on-treatment characteristics were comparable between the treatment and the validation groups (Additional file 1). In the validation group, the Pearson's correlation between log 10 HBsAg and log 10 HBV DNA was 0.64 (P<0.001). The sensitivity, specificity, PPV and NPV using an HBsAg titre >1,500 IU/ml to predict HBV DNA levels of >20,000 IU/ml were 64%, 79%, 64% and 79%, respectively.
Discussion
In this study, we confirmed a good correlation between log 10 HBsAg and log 10 HBV DNA as demonstrated in previous reports [7] [8] [9] [10] , especially in patients with CH, HBeAg-positivity, ALT levels >40 IU/l, HBsAg titre >250 IU/ml or those receiving PEG-IFN treatment. In parallel to the log 10 HBV DNA, the log 10 HBsAg was high in both immune tolerance and immune clearance phases, and significantly decreased in the inactive carrier state and increased again in the reactivation phase. Log 10 HBsAg predicts log 10 HBV DNA independently, and we demonstrated this good predictivity for HBV DNA>20,000 IU/ml if HBsAg titre was >900 IU/ml at baseline and if HBsAg titre was >1,500 IU/ml during the first year of treatment, especially in the subgroup of CH patients with ALT levels >40 IU/l. Therefore, serum HBsAg titre might serve as a surrogate marker for serum HBV DNA levels in the management of CHB patients.
To search for the best candidates of HBsAg quantification with a greater correlation to serum HBV DNA levels, we identified a group of active HBV replication in patients with CH, HBeAg-positivity and those with higher ALT or HBsAg levels before and during treatment. The correlation coefficient in the subgroup of CH patients (0.61, n=200; P<0.001) was higher than LC (0.24, n=35) or HCC (0.06, n=16) patients. Because these patients had comparable ALT, HBsAg and HBV DNA levels, the repeated necroinflammation of hepatocytes in LC or HCC patients might cause incomplete clearance of intrahepatic HBV DNA and lead to the discrepancy between serum HBsAg and HBV DNA levels. In addition to log 10 HBsAg, the multivariate analyses also verified that ALT levels >40 IU/l and HBeAg-positivity could predict HBV DNA levels independently; however, the fluctuation of ALT levels and a growing number of HBeAgnegative patients at baseline and after effective anti-HBV treatment might preclude these two parameters for HBV DNA prediction in our clinical practice.
Our data confirmed the study by Ozaras et al. [10] , which showed a good correlation between log 10 HBsAg and log 10 HBV DNA in CHB patients treated with PEG-IFN, and such a correlation is higher than in those treated with 3TC, ADV or ETV. The correlation in the treatment group was generally lower than that in the baseline group, implicating a greater disproportionate rapid reduction of serum HBV DNA levels than HBsAg titre during effective antiviral therapy. This discrepancy between HBsAg and HBV DNA was even more evident in the treatments using nucleoside/nucleotide analogues targeting HBV polymerase to suppress viral replication but which spared viral proteins such as HBsAg translated from intrahepatic covalently closed circular DNA (cccDNA) [8, 13, 16] . This speculation was further strengthened by the observation, in subgroup analysis, which showed the lowest correlation in those treated with ETV, the most potent antiviral agent. By contrast, we found the highest correlation between HBsAg and HBV DNA, with a large and significant reduction of HBsAg, with PEG-IFN treatment, which suggests that PEG-IFN has dual antiviral and immunomodulatory effects to control HBV replication and clearance of intrahepatic cccDNA.
For CHB patients and primary care physicians, the most important issues are the timing to start anti-HBV therapy and the responses during treatments. In treatment-naive patients with ALT levels >40 IU/l during periodic monitoring, we can check HBsAg titre first and verify the HBV DNA level if HBsAg titre is >900 IU/ml. Using this strategy to predict HBV DNA levels >20,000 IU/ml will achieve a higher PPV (84% versus 73%) compared with HBV DNA measurement in all patients with ALT levels >40 IU/l. In the first year of anti-HBV therapy, verifying treatment failure is important, and a first-year on-treatment HBsAg titre that is <1,500 IU/ml has a 90% chance of predicting HBV DNA<20,000 IU/ml, regardless of treatment regimen. This data will surely encourage continuing current treatment. Serial on-treatment HBsAg measurements after the first year of therapy also have the potential to predict corresponding HBV DNA changes.
Quantitative HBsAg titres have additional benefits in comparison with the readily available HBV DNA assays. Firstly, it is much more cost-effective (USD 8 versus 60 in Taiwan) during periodic monitoring [3] . Secondly, it might serve as a sensitive tool for blood screening with extremely low HBV DNA levels [6, 11] , an early detector of drug-resistant strains [8] , and an indicator of intrahepatic HBV DNA and cccDNA during or after PEG-IFN-based treatments [17] [18] [19] . Low pretreatment HBsAg titre, a rapid, early and greater reduction of HBsAg during PEG-IFN-based therapy and low end-oftreatment HBsAg titre could predict sustained virological response and subsequent HBsAg seroclearance over time [13, 16, [20] [21] [22] [23] [24] . For example, a week 12 or end-oftreatment HBsAg titre that is <1,500 IU/ml could predict HBsAg seroclearance or could indicate favourable treatment responses [16, 21, 23] . In addition, a rapid ontreatment HBsAg reduction of >0.5 log 10 IU/ml during the first year of telbivudine therapy is highly predictive of future HBsAg clearance at 3 years of therapy [25] . Both physicians and patients can benefit from the use of quantitative HBsAg titre in the management of CHB.
The limitations of our study included its retrospective design and that the timings of on-treatment measurements were not well-controlled. However, to investigate the kinetics of on-treatment HBsAg titres were beyond the primary goal of this study. In addition, patients with genotype A or D infections were not included because these genotypes are rare in Taiwan. In unusual circumstances, such as very early HBV infection, occult HBV infection, immunosuppressive status or having HBsAg variants (for example, pre-S1 deletion), the HBsAg assay might yield false negative results [4, 26] ; however, the ARCHITECT ® (Abbott Laboratories) HBsAg assay has been proven to have good sensitivity to detect various HBsAg mutants [27] .
In conclusion, quantitative serum HBsAg titre can serve as a surrogate marker of serum HBV DNA levels in the management of CHB, especially in patients with CH, HBeAg-positivity, ALT levels >40 IU/l, HBsAg>250 IU/ ml and during PEG-IFN treatment. An HBsAg titre of >900 IU/ml at baseline or >1,500 IU/ml within first year of treatment could predict serum HBV DNA levels of >20,000 IU/ml. Future prospective studies are needed to validate the clinical usefulness of quantitative HBsAg titre in different aspects of chronic HBV infection. baseline group and the characteristics of the treatment and validation groups can be found at http://www. intmedpress.com/uploads/documents/AVT-10-OA1586_Su_Add_file.pdf
